Catalyst
Slingshot members are tracking this event:
Phase 1b COSMIC-021 Trial data of Exelixis'(EXEL) Cabozantinib + atezolizumab (TECENTRIQ) in Solid tumors to be presented February 13, 2020 at ASCO GU
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| EXEL | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 10, 2020
Occurred Source:
https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-encouraging-results-cabozantinib-combination
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cabozantinib, Atezolizumab, Tecentriq, Solid Tumors
